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Colorectal cancer (CRC), as all other cancers, seems to be geneti-
cally unstable. This instability can be of two kinds: chromosomal
instability (CIN) or microsatellite instability (MSI) (Lengauer et
al, 1997). Microsatellites are simple repeats, often a dinucleotide,
on non-coding regions of DNA, which could be located within
genes or in between genes (Weber and May, 1989). MSI was first
described in a set of unselected CRC (Ionov et al, 1993; Thibodeau
et al, 1993) and in hereditary non-polyposis colorectal cancer
(HNPCC) (Aaltonen et al, 1993; Lindblom et al, 1993). HNPCC
is caused by germ-line mutations in genes involved in DNA
mismatch repair (MMR) (Kinzler and Vogelstein, 1996). MSI can
be detected in more than 90% of HNPCC tumours (Aaltonen et al,
1993; Tannergård et al, 1997). This increased mutation rate is
obtained from a defective MMR. HNPCC patients have a better
prognosis than sporadic CRC cases (Fujita et al, 1996; Sankila
et al, 1996; Myrhoj et al, 1997; Percesepe et al, 1997).
Approximately 12–17% of the unselected tumours also show MSI
(Aaltonen et al, 1993; Ionov et al, 1993; Thibodeau et al, 1993).
Very few mutations in MMR genes have been found in unselected
MSI-positive tumours. However, using immunohistochemistry, it
has been suggested that the MSI phenotype even in unselected
MSI-positive tumours involves lack of MMR gene function. In 14
out of 15 MSI-positive tumours tested, the expression of either
hMLH1 or hMSH2 was lacking (Thibodeau et al, 1996; Dietmaier
et al, 1997). A possible mechanism for this can be inactivation of
the hMLH1 gene by hypermethylation of its promotor (Kane et al,
1997; Herman et al, 1998). In accordance with this, patients with
sporadic or unselected CRC displaying MSI have been suggested
to have a better prognosis than those without (Lothe et al, 1993;
Thibodeau et al, 1993; Bubb et al, 1996). In the current study we
wanted to explore further the relations between MSI status and
prognosis in unselected CRC, in a large consecutive series of CRC
tumours obtained from two surgery clinics, and previously studied
for prognostic correlation to various parameters.
MATERIALS AND METHODS
Patients
One hundred and eighty-one unrelated patients with CRC treated
at the Departments of Surgery in Uppsala and Falun between 1988
and 1992 were included in the study. Adjuvant preoperative
radiotherapy was given to 28 of 62 patients with rectal cancer,
and one patient with colon cancer had post-operative adjuvant
chemotherapy. The tumours were graded according to the WHO
classification system (Morson and Sobin, 1976), and staged
according to the Dukes’ classification system (Dukes and Bussey,
1958). Clinicopathological characteristics are given in Table 1.
DNA extraction
The samples were frozen and stored at –70°C prior to DNA
extraction. DNA was prepared by proteinase-K digestion and
phenol–chloroform extraction according to standard procedures.
Microsatellite analysis
Dinucleotide repeats D22S428, D22S272, PDGF and mono-
nucleotide repeats transforming growth factor beta receptor
2 (TGF-b-R II), BAT-26, BAT-25 were used to type all tumours
with normal DNA available. For the 86 tumours where no normal
DNA was available, only the three mononucleotide markers were
used. Primers specific for each locus were used to amplify the
repeat and short flanking sequences in template DNA by poly-
merase chain reaction (PCR). One of the primers was labelled with
g[32P]dCTP prior to amplification. PCR was performed on normal
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and tumour DNA using 50 ng of purified genomic DNA in a final
volume of 20 ml. PCR conditions were 95°C for 2 min followed by
35 cycles (94°C for 45 s, 50–60°C for 45 s and 70°C for 1 min),
and a final elongation at 70°C for 7 min. Reactions were resolved
on urea-formamide polyacrylamide gel and exposed to film.
MSI analysis
Criteria used for MSI in our material are as follows: for samples,
where both normal and tumour material were available, six markers
were used and MSI defined as an alteration in at least three out of
six markers. In 86 samples where constitutional DNA was not
available, MSI was defined as an alteration in at least two loci of
three tested markers. Tumours showing one alteration but not
fulfilling the criteria above called MSI low (MSI-L) (Boland et al,
1998; Perucho, 1999) were considered as MSI-negative tumours in
the analysis.
Statistical analysis
Cause-specific survival analysis (death from colorectal cancer)
was analysed with the Cox proportional hazard model. Survival
curves were constructed using the Kaplan–Meier method, and
differences tested using the log-rank test. The c2 test was used to
test for differences in distribution among groups. Correlation coef-
ficients were calculated when testing correlation among groups
(Cox, 1972; Peto et al, 1977). The statistical software Statistica
(Statsoft Inc® version 5.0) was used for the analyses.
RESULTS
In 93 tumours with normal DNA available, we found 11 tumours
(12%), with MSI according to the criteria of at least three of six
markers used, and in tumours without normal DNA available, 11
tumours (12%) showed MSI according to the criteria of at least
two of three mononucleotide markers showing additional bands.
Thus, in accordance with previous studies we detected 12% MSI
positive tumours in this unselected material of CRC. The mean age
of onset of CRC was 69 years (range 39–91).
As expected, of the 22 MSI-positive tumours, the vast majority, 18
(81%), was found in the proximal colon. There was no correlation
between MSI status and age or gender (Table 1). None of the 24
Dukes’ D tumours were shown to be MSI-positive. The MSI-positive
tumours seem to be of a generally earlier stage. There were no statis-
tically significant differences between MSI-positive and MSI-nega-
tive tumours compared by each stage (Table 1).
Table 1 MSI status in colorectal cancer and its relation to age, gender, tumour stage, tumour differentiation and tumour localization
Number of Number of P-value Number of cancer related deaths
case MSI+ (%) tumours
MSI+ (%) MSI– (%)
Age NS
≤ 70 83 6 (7) 1 (17) 29 (38)
> 70 98 16 (16) 4 (25) 34 (41)
Gender NS
Male 78 14 (10) 2 (14) 31 (48)
Female 103 8 (14) 3 (3) 32 (34)
Tumour stage NS
A 28 4 (14) 0 (0) 3 (12)
B 92 15 (16) 3 (20) 17 (22)
C 37 3 (8) 2 (66) 19 (56)
D 24 0 0 (0) 24 (10)
Tumour differentiationa NS
Good 25 2 (8) 0 (0) 4 (17)
Moderate 120 16 (13) 4 (25) 40 (38)
Poor 36 4 (11) 1 (25) 19 (59)
Tumour localization 0.075
Proximal colon 119 19 (15) 4 (21) 27 (27)
Distal colon
(Including rectum) 62 3 (5) 1 (33) 36 (61)
aAccording to the WHO classification. NS, not significant.
Table 2 Univariate analyses showing the MSI status, gender, age, Dukes’
stages and tumour differentiation on prognosis of 181 patients
Variable P-value RH CI
MSI
MSI+ 1.0 Ref
MSI– 0.20 1.81 0.73–4.44
Gender
Male 1.0 Ref
Female 0.10 0.68 0.42–1.08
Age 0.10 1.02 0.99–1.08
Dukes’
A 1.0 Ref
B 0.15 2.43 0.72–8.14
C 0.001 7.61 2.26–25.5
D 0.0001 47.7 13.9–163.2
Tumour differentiation
Good 1.0 Ref
Moderate 0.048 2.8 1.0–2.86
Poor 0.002 5.4 1.82–15.8
RH, relative hazard.192 S Salahshor et al
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At follow-up, 68 patients (39%) had died from cancer, or from
other causes, but with a known tumour burden. The median
survival time of the living patients was 87 months (range 51–106).
Univariate survival analyses showed, as expected, a very strong
correlation between Dukes’ stage and prognosis, and a weaker but
statistically significant correlation between tumour differentiation
and prognosis (Table 2).
Survival analysis revealed no statistically significant difference
in prognosis between MSI-positive and MSI-negative cases (Table
2), although a trend towards better survival for MSI-positive cases
was observed (Figure 1). Survival analysis using Cox proportional
hazard model confirmed the lack of significant correlation
between MSI-positive tumours and prognosis (data not shown).
DISCUSSION
Our result did not show a significant correlation between MSI-
positive unselected colorectal tumours and good prognosis,
compared to previous studies (Lothe et al, 1993; Thibodeau et al,
1993; Bubb et al, 1996). In this study, we used both mononucleo-
tide markers and dinucleotide markers, including BAT-26, to test
for MSI status. Previous studies mostly used different numbers of
dinucleotide markers. Thibodeau et al (1993) used the criteria one
or more alterations out of four markers, and Lothe et al (1993)
used two or more alterations out of seven markers. Bubb et al used
one or more alterations out of four dinucleotide markers, plus
BAT-26. BAT-26, a quasimonomorphic marker (Figure 2), has
been shown to be sufficient alone to give the MSI status of
tumours even without normal DNA available (Bocker et al, 1997;
Hoang et al, 1997; Zhou et al, 1998). However, in the study by
Bubb et al (1996) BAT-26 was altered in only 58% of the tumours
having at least one alteration found with the other four markers.
Besides, BAT-26 alone identified three additional tumours in the
latter study. Since this report indicated that there could be tumours
showing MSI with dinucleotide markers but not BAT-26, we used
additional dinucleotide markers (D18S70, D18S461, D18S58,
D18S485, D18S483, D18S470, S18S1145, D18S57, D18S66) for
the 93 tumours with normal DNA available. This test identified
one more tumour to score as MSI-positive, because of dinucleotide
markers, while BAT-26 was negative. It also showed that two
tumours scored MSI-positive because of alterations in mono-
nucleotide markers should have been MSI negative if only di-
nucleotide markers were used. It is possible that mono- and
dinucleotide markers to some extent will identify different
tumours as MSI-positive, but this does not explain the lack of
statistically significance results obtained in our study.
We also found seven tumours expressing a low degree of MSI
(MSI-L). Five of those had an alteration in one out of three
mononucleotide markers and, the other two had one and two alter-
ations, respectively, in six markers.
To test if our criteria for MSI were too stringent, we included the
seven MSI-L tumours among the MSI-positive in a separate
survival analysis. The correlation obtained was even less (data are
not shown), indicating that the lack of correlation to prognosis was
not dependent on too strict criteria used for typing a tumour as MSI.
Bubb et al carried out the survival analysis on 169 patients and
the hazard ratio of patients with tumours showing MSI to those
without was estimated to be 0.39 (Bubb et al, 1996). Lothe et al
who studied 238 tumours using univariate cause specific (death by
colorectal cancer) analysis found a significant association between
MSI-positive and prolonged survival, the estimated hazard ratio
was 0.3 (Lothe et al, 1993). Thibodeau et al also used univariate
analysis of 86 patients with stage A to D colorectal cancer and
found a correlation between MSI positive and overall survival
(P = 0.02) (Thibodeau et al, 1993). Relative hazard estimated in
our material was 0.55.
A correlation between Dukes’ stage and MSI status in one set of
tumours could give false significance. In Lothe’s and Thibodeau’s
studies the significance was lost when Dukes’ stage was corrected
for in the analysis. However, in the Bubb study, where the signifi-
cance was highest, there was no correlation between Dukes’ stage
and MSI status. In our study there was no significant difference
between MSI-positive and MSI-negative tumours, if compared for
each stage. Thus, the differences in prognosis seen in Figure 1,
might be related to tumour stage at diagnosis in the MSI-positive
tumours. It is possible that this tendency to a lower tumour stage at
diagnosis might be related to a less malignant clinical courses. One
explanation for this could be a more efficient immune defence in
this group of patients.
In conclusion, although our results suggest that the presence of
MSI indicates a weak favourable clinical courses, in a series of
consecutive unselected CRC, MSI status is not an independent
prognostic factor.
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Figure 1 Life-table plots for all patients (Dukes’ stages A–D). MSI-positive
(––) versus MSI-negative (- - -). O indicates code for complete responses,
and + code for censored responses (i.e. patients who are alive or who have
died from other causes than cancer)
Figure 2 Microsatellite analysis with BAT-26 marker. MSI-positive tumours
have been indicated by arrowsMicrosatellite instability in sporadic colorectal cancer 193
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